FR3111560B1 - Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet - Google Patents

Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet Download PDF

Info

Publication number
FR3111560B1
FR3111560B1 FR2106376A FR2106376A FR3111560B1 FR 3111560 B1 FR3111560 B1 FR 3111560B1 FR 2106376 A FR2106376 A FR 2106376A FR 2106376 A FR2106376 A FR 2106376A FR 3111560 B1 FR3111560 B1 FR 3111560B1
Authority
FR
France
Prior art keywords
mesh
disinfection
irradiance
ultraviolet
ray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2106376A
Other languages
English (en)
Other versions
FR3111560A1 (fr
Inventor
Thomas Zunino
Jules Gouret
Nawel Himdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Zunino Innovation Conseil
Original Assignee
Thomas Zunino Innovation Conseil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Zunino Innovation Conseil filed Critical Thomas Zunino Innovation Conseil
Publication of FR3111560A1 publication Critical patent/FR3111560A1/fr
Application granted granted Critical
Publication of FR3111560B1 publication Critical patent/FR3111560B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Theoretical Computer Science (AREA)

Abstract

Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet L’invention porte principalement sur un procédé de détermination d’un champ d’irradiance dans une zone de désinfection (1) d’un système de désinfection (2) par irradiation ultraviolette, comprenant les étapes de : i. Génération d’un maillage par discrétisation de la zone de désinfection (1) ; ii. Attribution à chaque maille de paramètres optiques ; iii. Initialisation d’un champ d’irradiance ; iv. Modélisation de l’émission d’au moins un rayon lumineux de puissance et d’orientation déterminées ; v. Suivi du rayon émis modélisé et, pour chaque maille ayant rencontré le rayon, détermination d’une nouvelle valeur d’irradiance pour ladite maille et détermination de nouvelles valeurs de puissance et d’orientation d’au moins un nouveau rayon ; vi. Répétition de l’étape précédente tant qu’au moins un rayon modélisé suivi se propage dans la zone de désinfection (2), et vii. Détermination d’une valeur d’irradiance finale de chaque maille et détermination du champ d’irradiance final du maillage. Figure à publier avec l’abrégé : Figure 4
FR2106376A 2019-03-05 2021-06-16 Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet Active FR3111560B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (fr) 2019-03-05 2020-03-05 Procédés de traitement de l'amylose al
IBPCT/2020/000186 2020-06-17

Publications (2)

Publication Number Publication Date
FR3111560A1 FR3111560A1 (fr) 2021-12-24
FR3111560B1 true FR3111560B1 (fr) 2024-03-22

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2106376A Active FR3111560B1 (fr) 2019-03-05 2021-06-16 Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet

Country Status (16)

Country Link
US (2) US11692024B2 (fr)
EP (1) EP3934689A1 (fr)
JP (1) JP2022522889A (fr)
KR (1) KR20220019656A (fr)
CN (1) CN113811332A (fr)
AU (1) AU2020231081A1 (fr)
BR (1) BR112021017550A2 (fr)
CA (1) CA3132780A1 (fr)
CL (1) CL2021002318A1 (fr)
FR (1) FR3111560B1 (fr)
IL (1) IL286040A (fr)
JO (1) JOP20210245A1 (fr)
MA (1) MA55209A (fr)
MX (1) MX2021010665A (fr)
SG (1) SG11202109645QA (fr)
WO (1) WO2020178638A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109645QA (en) * 2019-03-05 2021-10-28 Prothena Biosciences Ltd Methods of treating al amyloidosis
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
AU2023207665A1 (en) * 2022-01-11 2024-07-25 Prothena Biosciences Limited Methods of treating al amyloidosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US8791243B2 (en) 2007-12-28 2014-07-29 Onclave Therapeutics Limited Treatment and prophylaxis of amyloidosis
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
IN2014CN03555A (fr) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
KR101759694B1 (ko) 2011-10-28 2017-07-19 인테그리티 바이오, 아이엔씨. 아미노산을 함유하는 단백질 제제
CA2956820A1 (fr) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Immunotherapie de ciblage de l'amyloidose
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
KR20210143752A (ko) 2019-02-12 2021-11-29 프로테나 바이오사이언시즈 리미티드 항체-생산 세포 및 기타 면역 세포 상의 cd38 세포 막 분자 및 면역글로불린 경쇄에 대한 단일클론 항체들의 조합을 이용한 al 아밀로이드증의 치료
SG11202109645QA (en) * 2019-03-05 2021-10-28 Prothena Biosciences Ltd Methods of treating al amyloidosis

Also Published As

Publication number Publication date
FR3111560A1 (fr) 2021-12-24
US20230331831A1 (en) 2023-10-19
BR112021017550A2 (pt) 2021-11-09
IL286040A (en) 2021-10-31
US20200308260A1 (en) 2020-10-01
JOP20210245A1 (ar) 2023-01-30
WO2020178638A1 (fr) 2020-09-10
JP2022522889A (ja) 2022-04-20
MX2021010665A (es) 2021-12-10
US11692024B2 (en) 2023-07-04
CL2021002318A1 (es) 2022-05-06
KR20220019656A (ko) 2022-02-17
CA3132780A1 (fr) 2020-09-10
EP3934689A1 (fr) 2022-01-12
AU2020231081A1 (en) 2021-09-30
CN113811332A (zh) 2021-12-17
MA55209A (fr) 2022-01-12
SG11202109645QA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
FR3111560B1 (fr) Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet
JP2017532543A (ja) 検出ゾーンの離散化
WO2019079417A3 (fr) Procédés de traitement laser de pièces transparentes au moyen de lignes focales de faisceau laser pulsé et de solutions de gravure chimique
JP2014089180A5 (fr)
RU2013132762A (ru) Лазерное устройство механической обработки и способ лазерной обработки, содержащие одиночную линзу для фокусировки
EP3918424A1 (fr) Modulations de lumière balistique pour une amélioration d'image à travers du brouillard
US20170363876A1 (en) Light irradiation device
US9995282B2 (en) Selectively perceptible wind turbine system
MX2021016073A (es) Funcionalidad de enfoque automático en el análisis óptico de muestras.
WO2016088721A8 (fr) Dispositif de surveillance de substrat et procédé de surveillance de substrat
KR101919735B1 (ko) 발광 빔 각도 조절이 가능한 광학계, 라이다 센서 및 이의 발광 각도 조절 방법
CN105676423A (zh) 一种透镜组件及得到无衍射光束的方法
JP4974117B2 (ja) 眼科用品の曲率の非接触測定方法とその方法を実装した測定装置
WO2021255348A1 (fr) Procédé de détermination dun champ dirradiance ultraviolette et dune durée optimale dirradiation ultraviolette en vue de la désinfection dune surface ou dun objet
FR2875295B1 (fr) Procede de mesure d'objets tridimensionnels par ombroscopie optique a une seule vue, utilisant les lois optiques de la propagation de la lumiere
RU2010123872A (ru) Способ и устройство для определения расхода протекающей жидкости
FR3057357B1 (fr) Procede et dispositif de detection et de caracterisation d'un element reflecteur dans un objet
FR3098683B1 (fr) Dispositif pour l’amélioration du rendement et de la qualité des végétaux par exposition aux UVs, procédé et utilisations associées
FR3083077B1 (fr) Procede de reconstruction tomographique differentielle
UA105123C2 (uk) Спосіб визначення потоків насичення регульованого перехрестя
FR3068127B1 (fr) Dispositif pour le diagnostic de systemes optroniques et procede associe.
RU2017132027A (ru) Способ снижения эффективной площади рассеивания оптико-электронного прибора
EA201501087A2 (ru) Система и способ определения режима работы светофоров на основе информации, получаемой с навигационных устройств
US20230185075A1 (en) System and method for adjusting one or more properties of a deformable lens
Zhukov et al. High-precision simulations of interaction of ultrashort laser pulses with bulk bandgap materials

Legal Events

Date Code Title Description
EXTE Extension to a french territory

Extension state: PF

PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20230728

PLFP Fee payment

Year of fee payment: 4